Silymarin in non alcoholic fatty liver disease

Table 1 Demographic, metabolic, serum liver-indices and ultrasonic data obtained before and after treatment in enrolled subjects (mean ± SD)

Variables	Before	After	P value
Age (yr)	44 ± 3.2
Sex (M/F)	40/32
BMI (kg/m2)	26.7 ± 1.67	26.4 ± 1.34	NS
Fasting plasma glucose (mg/mL)	105.7 ± 0.8	101 ± 0.5	NS
HOMA-IR	6.42 ± 0.4	5.27 ± 1.2	NS
Total Cholesterol (mg/dL)	205.7 ± 9.3	200.6 ± 8.1	NS
LDL-C (mg/mL)	157.4 ± 4.3	136 ± 1.8	NS
HDL-C (mg/mL)	43.6 ± 2.1	45.8 ± 1.1	NS
Triglycerides (mg/mL)	178.4 ± 4.1	155.7 ± 3.4	NS
Steato test	0.71 ± 0.07	0.40 ± 0.05	< 0.001
ALT (U/L)	109.48 ± 4.4	75.12 ± 3.3	< 0.01
AST (U/L)	72.39 ± 8.4	48.65 ± 3.2	< 0.01
AST/ALT ratio	0.66 ± 0.4	0.64 ± 0.9	NS
γ-GT (IU/L)	45.51 ± 1.2	29.33 ± 1.1	< 0.001
TNF-α (pg/mL)	16.2 ± 0.9	9.7 ± 0.7	< 0.001
Hepatorenal ratio	2.5 ± 0.3	1.8 ± 0.6	< 0.05

M/F: Male/female; BMI: Body mass index; HOMA-IR: Homeostatic model assessment insulin resistance; LDL: Low density lipoprotein; HDL: High density lipoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; γ-GT: Gamma glutamyl transpeptidase; TNF-α: Tumor necrosis factor-α; NS: Not significant.